2017 Retinal Pharmaceuticals and Biologics Report
A Global Market Analysis for 2016 to 2022

88 CHARTS AND TABLES
261 COMPREHENSIVE PAGES
27 COMPANY PROFILES
8 GEOGRAPHIC AND ECONOMIC BREAKOUTS
The 2017 Retinal Pharmaceuticals and Biologics Report has significant enhancements from previous reports, with updated estimates of the prevalence of diabetes and new extended analysis and discussions of diseases.

What's New

Author
Peter Downs

Released
October 2017

Market Scope's 2017 Retina Pharmaceuticals and Biologics Report provides in-depth coverage of current and future pharmaceuticals and biologics used in treating retinal diseases.

Eight Categories Are Analyzed In This Report:
- VEGF Inhibitors, PDGF Inhibitors, Neuroprotectors, Complement Cascade Inhibitors, Visual Cycle Modulators, Gene Therapies, Corticosteroids, and Other Mechanisms of Action

Each Market Segment Includes:
An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

Also Included in This Report:
- Review of Retinal Diseases and Treatments
- Symptoms, Diagnosis, and Treatment of AMD
- Diagnosis and Management of Diabetic Retinopathy and Macular Edema
- An Overview of Other Retinal Diseases and Conditions
- Epidemiology of Retinal Disease
- Patient Economics and Reimbursement
- Retina Specialists and Training
- Current Retinal Pharmaceuticals in the Marketplace
- 27 Company Profiles
- 41 Color Tables and 47 Color Figures

$264 Million in Manufacturer Revenues in 2017

IVT Compounded Cancer Drugs: 4.9%
Steroids, Time Release, Other IVT: 5.4%
Other (Oral and Topical): 0.2%
Ophthalmic Labeled Anti-VEGF: 89.4%
Our report on the retinal pharmaceuticals and biologics market is in its eighth edition. It is a leading industry source for accurate and relevant information on all aspects of the market. We cover prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We discuss the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and analyze treatment patterns and trends. We also forecast product demand in units and dollars, and we analyze market shares by product category.

> This report includes market data for 2016, and we forecast market performance through 2022.

How to Order

Order your 2017 Retinal Pharmaceuticals and Biologics Market Report now at www.market-scope.com or contact us directly via email or phone.

**ENTERPRISE LICENSE**

2017 Retinal Pharmaceuticals and Biologics Report

$10,200

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*

**SINGLE-USER LICENSE**

2017 Retinal Pharmaceuticals and Biologics Report

$6,800

Additional Printable Electronic PDF

$500

Additional Paper Copy

$300

**ADD-ONS**

- Disease Model by Country
- Custom Market Analysis

$ CALL FOR PRICING

314.835.0600 | info@market-scope.com

*Please add $50 for shipping if ordering from outside the US.*

Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

- Our proprietary global disease population and demographic models
- Twenty years and counting of ophthalmologist survey data
- Analysis of company published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in major, worldwide ophthalmic meetings
- Interviews and long-standing relationships with company executives and ophthalmologists
We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return-on-investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.